We are live on
!
Find out more
Federated Hermes Portfolio holdings
AUM
$69.6B
1-Year Est. Return
42.52%
This Fund
S&P 500
This Quarter
Est. Return
+13.69%
1 Year Est. Return
+42.52%
3 Year Est. Return
+132.48%
5 Year Est. Return
+152.58%
10 Year Est. Return
+652.43%
AUM
$53.1B
AUM Growth
+$6.76B
(+15%)
Cap. Flow
+$2.33B
Cap. Flow
% of AUM
4.39%
Top 10 Holdings %
Top 10 Hldgs %
14.65%
Holding
2,220
New
169
Increased
729
Reduced
1,033
Closed
165
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zscaler
ZS
|
+$222M |
| 2 |
Palantir
PLTR
|
+$221M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$213M |
| 4 |
FirstEnergy
FE
|
+$189M |
| 5 |
Broadcom
AVGO
|
+$174M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$383M |
| 2 |
Philip Morris
PM
|
+$280M |
| 3 |
Entergy
ETR
|
+$207M |
| 4 |
Paychex
PAYX
|
+$206M |
| 5 |
Gilead Sciences
GILD
|
+$201M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.81% |
| 2 | Healthcare | 14.57% |
| 3 | Financials | 13.43% |
| 4 | Industrials | 10.29% |
| 5 | Consumer Discretionary | 9.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
601
Keros Therapeutics
KROS
$223M
| $8.73M | 0.02% |
654,030
-570,109
| -47% | -$7.7M |
|
602
Adient
ADNT
$1.45B
| $8.72M | 0.02% |
448,022
-76,319
| -15% | -$1.13M |
|
603
Alibaba
BABA
$279B
| $8.67M | 0.02% |
76,415
-23,838
| -24% | -$2.82M |
|
604
Royal Bank of Canada
RY
$284B
| $8.59M | 0.02% |
65,264
-1,071
| -2% | -$131K |
|
605
Scholar Rock
SRRK
$7.22B
| $8.54M | 0.02% |
241,000
+238,791
| +10,810% | +$7.5M |
|
606
Clear Secure
YOU
$4.54B
| $8.52M | 0.02% |
306,924
-257,104
| -46% | -$6.55M |
|
607
Universal Technical Institute
UTI
$1.19B
| $8.52M | 0.02% |
251,269
+1,074
| +0.4% | +$33.7K |
|
|
WCC
608
WESCO International
WCC
$17.1B
| $8.49M | 0.02% |
45,837
-6,226
| -12% | -$1.03M |
|
|
GAP
609
The Gap Inc
GAP
$7.48B
| $8.44M | 0.02% |
386,897
-1,427,050
| -79% | -$31.9M |
|
610
Green Plains
GPRE
$984M
| $8.41M | 0.02% |
1,394,570
-432,185
| -24% | -$1.91M |
|
611
The RMR Group
RMR
$333M
| $8.36M | 0.02% |
511,316
-27,784
| -5% | -$426K |
|
612
Shell
SHEL
$250B
| $8.34M | 0.02% |
118,448
-2,668
| -2% | -$179K |
|
613
Alignment Healthcare
ALHC
$2.81B
| $8.32M | 0.02% |
594,489
+13,206
| +2% | +$213K |
|
614
Atmus Filtration Technologies
ATMU
$3.98B
| $8.32M | 0.02% |
228,507
-120,662
| -35% | -$4.3M |
|
615
Takeda Pharmaceutical
TAK
$57.6B
| $8.26M | 0.02% |
534,027
-7,892
| -1% | -$117K |
|
616
Unilever
UL
$139B
| $8.24M | 0.02% |
119,812
+24,680
| +26% | +$1.73M |
|
617
Brixmor Property Group
BRX
$8.93B
| $8.21M | 0.02% |
315,459
-2,842
| -0.9% | -$72.2K |
|
618
Telefônica Brasil
VIV
$18.1B
| $8.14M | 0.02% |
713,677
+100,762
| +16% | +$990K |
|
619
C3.ai
AI
$1.61B
| $7.98M | 0.02% |
324,592
-65,263
| -17% | -$1.49M |
|
620
Nucor
NUE
$57.3B
| $7.86M | 0.01% |
60,709
-14,475
| -19% | -$1.69M |
|
621
Travere Therapeutics
TVTX
$6.36B
| $7.81M | 0.01% |
527,538
-145,110
| -22% | -$2.41M |
|
|
TMHC
622
DELISTED
Taylor Morrison
TMHC
| $7.77M | 0.01% |
126,522
-17,246
| -12% | -$1M |
|
623
Ecolab
ECL
$80.1B
| $7.76M | 0.01% |
28,809
-36,127
| -56% | -$9.18M |
|
624
Bumble
BMBL
$358M
| $7.73M | 0.01% |
1,173,055
+428,559
| +58% | +$2.16M |
|
625
ON Semiconductor
ON
$29.1B
| $7.71M | 0.01% |
147,102
-332,376
| -69% | -$14.4M |
|
Similar funds
Federated Hermes's Q2 2025 Portfolio in Review
As of Q2 2025, Federated Hermes held 2,220 positions worth $53.1B, up 15% from $46.4B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Federated Hermes deployed $2.33B of net new capital in Q2 2025, opening 169 new positions and adding to 729 existing holdings. Its largest new stake was Genuine Parts: 882,160 shares worth $107M.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 20% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $383M trimmed.
- Federated Hermes's largest Q2 2025 buy was Genuine Parts: 882,160 shares worth $107M.
- Federated Hermes added most to Zscaler in Q2 2025, an estimated $222M increase.
- Federated Hermes's biggest Q2 2025 reduction was Bristol-Myers Squibb, cutting an estimated $383M.
- Federated Hermes fully exited Regulus Therapeutics in Q2 2025, selling an estimated $39.2M.
- Federated Hermes's ten largest holdings make up 15% of its $53.1B portfolio in Q2 2025.
- Federated Hermes opened 169 new positions and closed 165 in Q2 2025.
- Federated Hermes's portfolio value rose 15% quarter-over-quarter to $53.1B.
Based on Federated Hermes's 13F filing for Q2 2025, filed 13 Aug 2025.